Search

Your search keyword '"Xiaozheng Huang"' showing total 2 results
Start Over Author "Xiaozheng Huang" Publisher china anti-cancer association
2 results on '"Xiaozheng Huang"'

1. The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series

Author

Jianghua Wu, Wei Sun, Haiyue Wang, Xiaozheng Huang, Xinyu Wang, Weiyang Jiang, Ling Jia, Ping Wang, Qin Feng, and Dongmei Lin

Subjects
lung adenocarcinoma, pd-l1 expression, classical genomic aberrations, molecular biomarkers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

ObjectiveTo investigate the correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma (LADC) patients.MethodsWe reviewed 428 consecutive, surgically resected cases of LADC from October 2015 to December 2016 from our center. PD-L1 expression was evaluated based on tumor proportion score (TPS). Correlation and co-occurrence of PD-L1 expression level with those of classical driver genes, such as EGFR, ALK, ROS-1, and KRAS and with clinical variables and disease-free survival (DFS) were analyzed.ResultsSeventy of the 428 cases (16.4%) showed TPS ≥ 1%, and 21 cases (4.9%) showed TPS ≥ 50%. PD-L1 positive expression was significantly associated with male gender, smoking, advanced TNM stage, and solid histologic subtype. Both TPS ≥ 1% and ≥ 50% were correlated with the absence of an EGFR mutation (P < 0.001) and the presence of ALK rearrangement (P = 0.024). KRAS mutation was associated with TPS ≥ 50% (P = 0.035). PD-L1 positivity commonly overlapped with the alterations of classical driver oncogenes (58.5% with TPS ≥ 1% and 42.9% with TPS ≥ 50%). Approximately three-quarters of PD-L1 positive cases co-occurred with classical therapeutic-gene aberrations in cases with stage III/IV cancer or cancer progression. LADC could be divided into four subgroups based on the expression profile of current routine biomarkers for potential therapeutic strategies.ConclusionsPD-L1 expression is not only closely correlated with classic gene alterations but also commonly overlaps with the aberrations of classical driver oncogenes in Chinese LADC patients. These findings provide a useful overview of clinical strategies that rely on the profile of routinely used molecular biomarkers.

Published
2019
Full Text
View/download PDF

2. The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series

Author

Xinyu Wang, Xiaozheng Huang, Wei Sun, Ling Jia, Ping Wang, Jianghua Wu, Qin Feng, Dongmei Lin, Weiyang Jiang, and Haiyue Wang

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Single Center, medicine.disease_cause, lcsh:RC254-282, molecular biomarkers, Correlation, 03 medical and health sciences, 0302 clinical medicine, classical genomic aberrations, Internal medicine, medicine, Stage (cooking), Lung, business.industry, Cancer, medicine.disease, lung adenocarcinoma, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, pd-l1 expression, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Adenocarcinoma, Original Article, Pd l1 expression, KRAS, business
Abstract

Objective: To investigate the correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chineselung adenocarcinoma (LADC) patients. Methods: We reviewed 428 consecutive, surgically resected cases of LADC from October 2015 to December 2016 from our center.PD-L1 expression was evaluated based on tumor proportion score (TPS). Correlation and co-occurrence of PD-L1 expression levelwith those of classical driver genes, such as EGFR, ALK, ROS-1, and KRAS and with clinical variables and disease-free survival(DFS) were analyzed. Results: Seventy of the 428 cases (16.4%) showed TPS ≥ 1%, and 21 cases (4.9%) showed TPS ≥ 50%. PD-L1 positive expressionwas significantly associated with male gender, smoking, advanced TNM stage, and solid histologic subtype. Both TPS ≥ 1% and ≥50% were correlated with the absence of an EGFR mutation (P < 0.001) and the presence of ALK rearrangement (P = 0.024).KRAS mutation was associated with TPS ≥ 50% (P = 0.035). PD-L1 positivity commonly overlapped with the alterations ofclassical driver oncogenes (58.5% with TPS ≥ 1% and 42.9% with TPS ≥ 50%). Approximately three-quarters of PD-L1 positivecases co-occurred with classical therapeutic-gene aberrations in cases with stage III/IV cancer or cancer progression. LADC couldbe divided into four subgroups based on the expression profile of current routine biomarkers for potential therapeutic strategies. Conclusions: PD-L1 expression is not only closely correlated with classic gene alterations but also commonly overlaps with theaberrations of classical driver oncogenes in Chinese LADC patients. These findings provide a useful overview of clinical strategiesthat rely on the profile of routinely used molecular biomarkers. Cite this article as: Wu J, Sun W, Wang H, Huang X, Wang X, Jiang W, et al.The correlation and overlaps between PD-L1 expression and classicalgenomic aberrations in Chinese lung adenocarcinoma patients: a single centercase series. Cancer Biol Med. 2019; 16: 811-21. doi: 10.20892/j.issn.2095-3941.2019.0209

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results